FibroGen (NASDAQ:FGEN) Full Year 2024 Results

Key Financial Results

• Revenue: US$29.6m (down 37% from FY 2023).
• Net loss: US$153.1m (loss narrowed by 53% from FY 2023).
• US$1.53 loss per share (improved from US$3.32 loss in FY 2023).

FGEN Products In Clinical Trials

• Phase I: 1.
• Phase II: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

FibroGen Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 35%.

Looking ahead, revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 16% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for FibroGen (2 can't be ignored!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.